Clinical trial
Buspirone for the Treatment of Anxiety in Williams Syndrome
NCT04807517 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Buspirone for the Treatment of Anxiety in Williams Syndrome
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 1, 2021
- Completion date
- September 11, 2023
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anxiety, williams syndrome